English

Choose language

Back

  • Deutsch

  • ελληνική

  • English

  • Español

  • Français

  • Polski

  • Português

  • Русский

  • Українська


English

How do you prefer to top up your account?

* We don't charge any commission for making deposits into your account

Shares Gilead Sciences

19.11%
Growth potential
59.89 USD
Price per share
USD
3.49%
Dividend income
Gilead Sciences sold by lots comprising 1 pc.
Enter the number of securities
Order price:
Brokerage commission:
Transfer commission:
Advancing therapeutics, improving lives
Why invest in Gilead Sciences?
  • One of the world's largest biotech companies
  • Net profit $2B in Q1 2019
  • A leading anti-HIV medical drug developer
  • Over $84B market cap


1d
1w
1mo
6mths
All the time
Recommendations of the largest investment banks
Morgan Stanley
Hold
67 USD
03.11.2020
UBS
Hold
61 USD
28.10.2020
Jefferies
Buy
78 USD
30.09.2020
Maxim Group
Buy
88 USD
15.09.2020
Financial indicators
Capitalization
93.06B USD
P / E
59.70
Profit
22.28B USD
Net profit
21.74B USD

Gilead Sciences is the largest American biopharmaceutical company engaged in research and development of healthcare products and has a batch production of innovative medicines. The Company was founded in 1987 by a 29-year-old doctor Michael L. Riordan. Gilead's technologies, as well as the drugs themselves, have established themselves as a leading choice when it comes to prevention and cure of the most fatal human diseases. The Company's main efforts have been focused on HIV cure development as well as various treatments of chronic hepatitis B and C, cancers, cardiovascular and respiratory diseases. Among the well-known products are Tamiflu, Atripla, Vistide, Emtriva. The latest successful project of Gilead was Sovaldi, which is an effective medicine for hepatitis C cure. The innovation has become an all-time record of sales. The company's research centers are located in the American cities of Boulder and San Dimas. The company has a rather small staff number, which is about 8,000 employees, with a fairly large turnover of almost $ 25 billion. Today Gilead Sciences boasts of being one of the most speedily developing start-ups in its field. Its headquarters are in California, though the company has its representative offices in other states of North America, as well as in Europe, Asia, and Australia.

Receive ideas for profitable investments - faster than the market

We will be sending you a letter once a week with the most relevant information

Congratulations!

Now you will always be aware of which stocks are more profitable to invest in